Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 16/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 12/20 | 0.38 |
| ▸ | ITGAV | P06756 | 12/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KLK7 | P49862 | 1/20 | 0.32 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
| ▸ | CASP6 | P55212 | 1/20 | 0.32 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7347915 | 0.77 | ITGB3 (0.46) | ITGB3ITGA2BITGAV | |
| SCHEMBL8549358 | 0.69 | ITGB3 (0.45) | ITGB3ITGA2BITGAV | |
| SCHEMBL8549373 | 0.68 | ITGB3 (0.38) | ITGB3ITGA2BITGAVMAPTKLK7 | |
| SCHEMBL7358961 | 0.65 | ITGB3 (0.52) | ITGB3ITGA2BITGAV | |
| SCHEMBL7350957 | 0.64 | ITGB3 (0.44) | ITGB3ITGA2BITGAV | |
| SCHEMBL8646891 | 0.63 | ITGB3 (0.40) | ITGB3ITGA2BITGAVKLK7KLK5 | |
| SCHEMBL6380611 | 0.63 | MEN1 (0.57) | — | |
| SCHEMBL8646928 | 0.62 | ITGB3 (0.39) | ITGB3ITGA2BITGAVKLK7KLK5 | |
| SCHEMBL4707157 | 0.59 | MEN1 (0.52) | — | |
| SCHEMBL567435 | 0.59 | MEN1 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1998043962-A1 | HETEROCYCLIC INTEGRIN INHIBITOR PRODRUGS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-10-08 | — | — | WO | disclosed |